CELYAD SA/ADR (CYAD) Upgraded to “Buy” by Zacks Investment Research

CELYAD SA/ADR (NASDAQ:CYAD) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a note issued to investors on Tuesday, Zacks.com reports. The brokerage presently has a $21.00 price objective on the stock. Zacks Investment Research‘s price target would indicate a potential upside of 4.37% from the company’s current price.

According to Zacks, “Celyad SA is a biopharmaceutical company. The Company develops and commercializes cell based regenerative therapies to treat illnesses where cardiac tissue is lost due to chronic or acute injury. Celyad SA is based in Mont-Saint-Guibert, Belgium. “

A number of other research analysts have also recently issued reports on CYAD. HC Wainwright reissued a “buy” rating and set a $52.00 price target on shares of CELYAD SA/ADR in a research report on Friday, May 17th. Piper Jaffray Companies lowered their price target on shares of CELYAD SA/ADR from $51.00 to $41.00 and set an “overweight” rating for the company in a research report on Monday, April 1st. Finally, William Blair reissued a “buy” rating on shares of CELYAD SA/ADR in a research report on Monday, March 18th. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $41.40.

Shares of CYAD opened at $20.12 on Tuesday. The stock has a market cap of $198.63 million, a PE ratio of -5.07 and a beta of 1.81. The company has a debt-to-equity ratio of 0.02, a quick ratio of 5.36 and a current ratio of 5.36. CELYAD SA/ADR has a 1-year low of $15.36 and a 1-year high of $32.18.

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Victory Capital Management Inc. raised its holdings in CELYAD SA/ADR by 4.0% in the first quarter. Victory Capital Management Inc. now owns 672,331 shares of the company’s stock worth $13,716,000 after buying an additional 25,980 shares during the last quarter. Millennium Management LLC raised its holdings in CELYAD SA/ADR by 69.6% in the fourth quarter. Millennium Management LLC now owns 90,597 shares of the company’s stock worth $1,645,000 after buying an additional 37,171 shares during the last quarter. Morgan Stanley raised its holdings in CELYAD SA/ADR by 29.9% in the first quarter. Morgan Stanley now owns 9,985 shares of the company’s stock worth $204,000 after buying an additional 2,298 shares during the last quarter. Finally, Wells Fargo & Company MN raised its holdings in CELYAD SA/ADR by 22.3% in the first quarter. Wells Fargo & Company MN now owns 7,614 shares of the company’s stock worth $155,000 after buying an additional 1,390 shares during the last quarter. 7.89% of the stock is owned by institutional investors.

CELYAD SA/ADR Company Profile

Celyad SA, a clinical-stage biopharmaceutical company, focuses on the development of CAR-T cell-based therapies. The company utilizes its expertise in cell engineering to target cancer. Its CAR-T cell platform has the potential to treats a range of solid and hematologic tumors. The company's lead drug product candidate, CYAD-01 (CAR-T NKG2D), has been evaluated in a Phase I clinical trial to assess the safety and clinical activity of multiple administrations of autologous CYAD-01 cells in seven refractory cancers, including five solid tumors, such as colorectal, ovarian, bladder, triple-negative breast, and pancreatic cancers; and two hematological tumors comprising acute myeloid leukemia and multiple myeloma.

Read More: Trading based on a resistance level

Get a free copy of the Zacks research report on CELYAD SA/ADR (CYAD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for CELYAD SA/ADR (NASDAQ:CYAD)

Receive News & Ratings for CELYAD SA/ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CELYAD SA/ADR and related companies with MarketBeat.com's FREE daily email newsletter.